GT Biopharma Statistics Share Statistics GT Biopharma has 3.56M
shares outstanding. The number of shares has increased by 40.89%
in one year.
Shares Outstanding 3.56M Shares Change (YoY) 40.89% Shares Change (QoQ) 24.11% Owned by Institutions (%) 4.25% Shares Floating 3.04M Failed to Deliver (FTD) Shares 548 FTD / Avg. Volume 0.52%
Short Selling Information The latest short interest is 261K, so 7.34% of the outstanding
shares have been sold short.
Short Interest 261K Short % of Shares Out 7.34% Short % of Float 7.42% Short Ratio (days to cover) 3.47
Valuation Ratios The PE ratio is -0.44 and the forward
PE ratio is -1.5.
GT Biopharma's PEG ratio is
-0.02.
PE Ratio -0.44 Forward PE -1.5 PS Ratio 0 Forward PS 0.3 PB Ratio -3.46 P/FCF Ratio -0.45 PEG Ratio -0.02
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for GT Biopharma.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 0.72,
with a Debt / Equity ratio of 0.
Current Ratio 0.72 Quick Ratio 0.72 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-13.16M Employee Count 1 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -51.79% in the
last 52 weeks. The beta is 1.37, so GT Biopharma's
price volatility has been higher than the market average.
Beta 1.37 52-Week Price Change -51.79% 50-Day Moving Average 1.87 200-Day Moving Average 2.35 Relative Strength Index (RSI) 26.74 Average Volume (20 Days) 105,659
Income Statement
Revenue n/a Gross Profit n/a Operating Income -14.36M Net Income -13.16M EBITDA -13.16M EBIT -13.16M Earnings Per Share (EPS) -6.94
Full Income Statement Balance Sheet The company has 3.95M in cash and 0 in
debt, giving a net cash position of 3.95M.
Cash & Cash Equivalents 3.95M Total Debt n/a Net Cash n/a Retained Earnings -695.23M Total Assets 7.12M Working Capital 4.82M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -12.9M
and capital expenditures 0, giving a free cash flow of -12.9M.
Operating Cash Flow -12.9M Capital Expenditures n/a Free Cash Flow -12.9M FCF Per Share -6.8
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields GTBP does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for GTBP is $11,
which is 1070.2% higher than the current price. The consensus rating is "Buy".
Price Target $11 Price Target Difference 1070.2% Analyst Consensus Buy Analyst Count 1
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Feb 5, 2024. It was a
backward
split with a ratio of 1:30.
Last Split Date Feb 5, 2024 Split Type backward Split Ratio 1:30
Scores Altman Z-Score -140.3 Piotroski F-Score 1
